| 02.12.2022 14:48 | DEST | Director Disclosure | RNS |
| 23.11.2022 07:00 | DEST | Appointment of Corporate Broker | RNS |
| 21.11.2022 14:19 | DEST | EQS-News: Destiny Pharma PLC 'leads the world' in new approach to preventing hospital infections | EQS |
| 18.11.2022 13:16 | DEST | Director Shareholding Amendment | RNS |
| 15.11.2022 16:16 | DEST | Destiny Pharma starts new drug study for its skin infection treatment | Alliance |
| 15.11.2022 07:00 | DEST | XF-73 advances to clinically enabling safety study | RNS |
| 31.10.2022 11:06 | DEST | Second Price Monitoring Extn | RNS |
| 31.10.2022 11:01 | DEST | Price Monitoring Extension | RNS |
| 22.09.2022 07:00 | DEST | Notice of R&D Update Meeting | RNS |
| 08.09.2022 15:17 | DEST | Destiny Pharma loss widens, pins hope on late stage clinical assets | Alliance |
| 08.09.2022 07:00 | DEST | Interim results for six months ended 30 June 2022 | RNS |
| 07.09.2022 17:21 | DEST | Destiny Pharma gets positive EMA feedback for gut bacteria treatment | Alliance |
| 07.09.2022 07:03 | DEST | Presenting at HC Wainwright Investment Conference | Reach |
| 07.09.2022 07:01 | DEST | Positive update from EMA on NTCD-M3 Phase 3 plans | RNS |
| 05.09.2022 14:15 | DEST | Expiry of Share Options | RNS |
| 01.09.2022 15:59 | VTY, SLP, SPI | UK earnings, trading statements calendar - next 7 days | Alliance |
| 22.08.2022 07:00 | DEST | Notice of Interim Results | RNS |
| 28.07.2022 07:00 | DEST | Chair’s Investor Update | RNS |
| 26.07.2022 22:16 | JARA, RCOI, OCI | TRADING UPDATES: De La Rue cancels contract; Apollon buys in Jamaica | Alliance |
| 26.07.2022 07:00 | DEST | Publication of new data on NTCD-M3 | RNS |
| 19.07.2022 20:01 | COPL, CCZ, PRD | TRADING UPDATES: Capital backs outlook; Northcoders trades well | Alliance |
| 19.07.2022 07:00 | DEST | Positive update from US FDA on XF-73 Phase 3 | RNS |
| 12.07.2022 12:07 | DEST | IN BRIEF: Destiny Pharma receives undisclosed grant for MRSA study | Alliance |
| 12.07.2022 07:00 | DEST | Grant from the Cystic Fibrosis Foundation | RNS |
| 07.07.2022 20:38 | DEST | IN BRIEF: Destiny Pharma XF-73 shown to enhance activity of two drugs | Alliance |
| 07.07.2022 07:00 | DEST | Publication of XF-73 drug synergy data | RNS |
| 05.07.2022 11:43 | DEST | IN BRIEF: Destiny Pharma begins research on XF-73 for oral mucositis | Alliance |
| 05.07.2022 07:00 | DEST | New XF-73 research programme | RNS |
| 08.06.2022 07:00 | DEST | Grant of share options | RNS |
| 27.05.2022 11:56 | DEST | Result of Annual General Meeting & Strategy Update | RNS |
| 26.05.2022 07:00 | DEST | Board Changes | RNS |
| 20.05.2022 16:00 | SXS, TRIG, OXB | UK shareholder meetings calendar - next 7 days | Alliance |
| 12.05.2022 19:45 | MTW, CMET, HEIQ | TRADING UPDATES: Belluscura to raise GBP5 million; React buys | Alliance |
| 12.05.2022 07:00 | DEST | Landmark NTCD-M3 data to be presented at Anaerobe | RNS |
| 03.05.2022 21:55 | HEIT, AAU, COPL | TRADING UPDATES: Vela, Standard Life Investments up portfolio value | Alliance |
| 03.05.2022 07:00 | DEST | Destiny Pharma appoints Dr Yuri Martina as CMO | RNS |
| 27.04.2022 15:34 | DEST | Posting of Annual Report and Notice of AGM | RNS |
| 26.04.2022 15:30 | DEST | Director/PDMR Shareholding | RNS |
| 12.04.2022 12:42 | SAAS, TM1, DEST | EARNINGS UPDATES: Parsley Box widens loss; M Winkworth profit doubles | Alliance |
| 12.04.2022 07:00 | DEST | Audited results for year ended 31 December 2021 | RNS |
| 05.04.2022 16:34 | PNN, NANO, MONY | UK earnings, trading statements calendar - next 7 days | Alliance |
| 04.04.2022 14:45 | DEST | Notice of Results | RNS |
| 04.04.2022 14:37 | DEST | Notification of Major Holdings | RNS |
| 31.03.2022 07:00 | DEST | To present data at ECCMID Congress | RNS |
| 28.03.2022 11:30 | DEST | Result of General Meeting and Total Voting Rights | RNS |
| 25.03.2022 14:26 | DEST | IN BRIEF: Destiny Pharma raises GBP450,000 through open offer | Alliance |
| 25.03.2022 07:00 | DEST | Result of Open Offer | RNS |
| 22.03.2022 10:30 | DEST | Exercise of Options and Total Voting Rights | RNS |
| 08.03.2022 19:38 | DEST | IN BRIEF: Destiny Pharma to raise GBP7.0 million for asset trials | Alliance |
| 08.03.2022 12:30 | DEST | Fundraising | RNS |
| 08.02.2022 07:00 | DEST | Positive feedback from EMA on XF-73 Nasal gel Ph 3 | RNS |
| 01.02.2022 16:11 | DEST | Exercise of Options and Total Voting Rights | RNS |
| 01.02.2022 07:00 | DEST | Positive data in XF-73 Dermal study with NIAID | RNS |
| 31.01.2022 14:30 | DEST | Exercise of Options and Total Voting Rights | RNS |
| 25.01.2022 07:00 | DEST | Grant of share options | RNS |
| 24.01.2022 07:00 | DEST | Clinical and commercial opportunity of NTCD-M3 | RNS |
| 21.01.2022 07:15 | DEST | Destiny Pharma Lancet Report | RNS |
| 17.01.2022 07:00 | DEST | Strategy/Company/Ops Update | RNS |
| 21.12.2021 16:35 | DEST | Exercise of Options and Total Voting Rights | RNS |
| 17.12.2021 09:46 | DEST | Grant of share options | RNS |
| 15.11.2021 14:26 | DEST | Directorate Change | RNS |
| 04.11.2021 07:00 | DEST | SAB Member Prof. Gerding is Keynote at C.diff Conf | Reach |
| 18.10.2021 07:00 | DEST | Study gives strong support for potential of XF-73 | RNS |
| 27.09.2021 15:18 | DEST | Director/PDMR Shareholding | RNS |
| 27.09.2021 07:00 | DEST | Expansion of clinical pipeline | RNS |
| 09.09.2021 07:00 | DEST | Interim results for six months ended 30 June 2021 | RNS |
| 23.08.2021 07:00 | DEST | Notice of Interim Results | RNS |
| 02.08.2021 07:00 | DEST | Secondary endpoint analysis from Phase 2b trial | RNS |
| 09.07.2021 08:00 | DEST | XF-73 Phase 2b data to be presented at ECCMID | RNS |
| 06.07.2021 07:00 | DEST | NTCD-M3 RD Agreement with US Dept Veterans Affairs | RNS |
| 02.07.2021 08:00 | DEST | Scientific Advisor Gerding chairs C Diff symposium | Reach |
| 29.06.2021 08:24 | DEST | DEST to present at Shares & AJ Bell Webinar 6/7/21 | RNS |
| 10.06.2021 17:00 | DEST | Director Dealing | RNS |
| 10.06.2021 07:00 | DEST | XF-73 data abstract to be presented at 2021 ECCMID | RNS |
| 07.06.2021 07:00 | DEST | Destiny Pharma welcomes G7’s Communique on AMR | RNS |
